AIDSWEEKLY Plus; Monday, August 20 & 27, 2001
AIDS Weekly Staff Writers

NewsRx - In preliminary laboratory studies, researchers at the University of Texas Medical Branch at Galveston (UTMB) have found what could prove to be a slick new weapon in the battle against AIDS: over-the-counter sexual lubricants.

Test-tube experiments show that three "personal lubricants" inhibit HIV production by more than 1,000-fold when mixed with virus-infected seminal fluid, suggesting that use of these substances might greatly reduce the transmission of HIV in locales where condoms are rarely used. Condoms remain the most effective barrier to acquiring AIDS during sexual intercourse, the researchers stress.

Microbiologists Samuel Baron, Joyce Poast, Derrick Nguyen, and Miles Cloyd published their discovery in the July 20, 2001, issue of AIDS Research and Human Retroviruses. It grew out of their earlier work showing that, thanks to its low-salt content, saliva kills HIV infected white blood cells and helps block oral transmission of the virus.

The investigators knew from previous research that the over-the-counter spermicide nonoxynol-9 could kill infected white blood cells, although studies show that it also may increase HIV transmission by irritating the mucous membranes of the vagina and rectum, causing lesions that offer the AIDS virus a portal into the body. Still, the UTMB researchers wondered whether other over-the-counter substances might offer similar antiviral effects without causing irritation. So they went to a local drug store and bought a wide variety of products designed for use in the vagina or rectum and then tested them.

These tests narrowed down 22 preparations to just three categorized as safe and effective by the U.S. Food and Drug Administration, all three of which killed substantial numbers of infected white blood cells, as well as free HIV, without irritating the tissues. Next, the researchers pitted the chosen substances against HIV infected cells suspended in seminal fluid.

The results were startling. Mixing the lubricants - substances sold as Astroglide, Silken Secret, and Vagisil - with HIV infected cells reduced viral output by more than 1,000 times. Layering them on top of HIV infected white blood cells cut virus production by more than 30 times. Moreover, components of the lubricants, currently being identified, deactivated the virus-bearing cells quickly, making a significant impact within five minutes, well short of the 30 minutes required for the infected cells to transmit HIV to the surface cells of the vagina and rectum.

The lubricants maintained their effectiveness even when diluted fourfold, and they protected against the virus even after spending eight hours incubating at 98.6°F.

As Baron sees it, the UTMB team's discovery might help reduce HIV transmission in places where condom use is far from routine. Even in the U.S., he points out, only 30% of sexually active people use condoms, while in some underdeveloped countries such use falls below 10%.

Baron cautions that it's a "big leap from the test tube to the real world." The latter requires a field trial in human beings of the three lubricants, which would cost about $3 million, he says. "No one should use these substances assuming that they will protect you from contracting HIV and from eventually getting AIDS until we have evidence from field trials answering that question," he adds.

As with any human experimentation, there are also cultural and ethical considerations. But Baron remains excited by the slippery substance's potential. "In countries where you have a 30% transmission rate per year," he says, "if you can reduce that by half, you can save a heck of a lot of people."

This article was prepared by AIDS Weekly editors from staff and other reports.

SOURCE: AIDS Res Hum Retroviruses 2001 Jul 20;17(11):997-1002.

010813
AW010805

Copyright © 2001 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.